Healthcare and Medicine Reference
In-Depth Information
111. Caneda-Ferron, B., De Girolamo, L. A., Costa, T., Beck, K. E., Layfield, R. &
Billett, E. E. (2008) Assessment of the direct and indirect effects of MPP+ and
dopamine on the human proteasome: implications for Parkinson's disease aetiol-
ogy. J. Neurochem. 105: 225-238.
112. McNaught, K. S., Bjorklund, L. M., Belizaire, R., Isacson, O., Jenner, P. & Olanow,
C. W. (2002) Proteasome inhibition causes nigral degeneration with inclusion
bodies in rats. Neuroreport 13: 1437-1441.
113. McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P. & Olanow, C. W. (2003)
Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179:
114. Lev, N., Melamed, E. & Offen, D. (2006) Proteasomal inhibition hypersensitizes
differentiated neuroblastoma cells to oxidative damage. Neurosci. Lett. 399:
115. Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W., Hendil, K. B. & Jensen,
P. H. (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers.
J. Biol. Chem. 279: 12924-12934.
116. Snyder, H., Mensah, K., Theisler, C., Lee, J., Matouschek, A. & Wolozin, B. (2003)
Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein
and inhibit proteasomal function. J. Biol. Chem. 278: 11753-11759.
117. Yuan, Y., Jin, J., Yang, B., Zhang, W., Hu, J., Zhang, Y. & Chen, N. H. (2008) Over-
expressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway.
Cell. Mol. Neurobiol. 28: 21-33.
118. Zhu, W., Li, X., Xie, W., Luo, F., Kaur, D., Andersen, J. K., Jankovic, J. & Le, W.
(2010) Genetic iron chelation protects against proteasome inhibition-induced
dopamine neuron degeneration. Neurobiol. Dis. 37: 307-313.
119. Li, X. P., Xie, W. J., Zhang, Z., Kansara, S., Jankovic, J. & Le, W. D. (2012) A mecha-
nistic study of proteasome inhibition-induced iron misregulation in dopamine
neuron degeneration. Neurosignals, forthcoming.
120. Bonilla, E. (2000) [Huntington disease. A review]. Invest. Clin. 41: 117-141.
121. Haddad, M. S. & Cummings, J. L. (1997) Huntington's disease. Psychiatr. Clin.
North Am. 20: 791-807.
122. Rosenblatt, A. & Leroi, I. (2000) Neuropsychiatry of Huntington's disease and
other basal ganglia disorders. Psychosomatics 41: 24-30.
123. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D. & Richardson,
E. P., Jr. (1985) Neuropathological classification of Huntington's disease. J. Neu-
ropathol. Exp. Neurol. 44: 559-577.
124. Andrew, S. E., Goldberg, Y. P., Kremer, B., Telenius, H., Theilmann, J., Adam, S.,
Starr, E., Squitieri, F., Lin, B. et al. (1993) The relationship between trinucleotide
(CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 4:
125. Sugars, K. L. & Rubinsztein, D. C. (2003) Transcriptional abnormalities in Hun-
tington disease. Trends Genet. 19: 233-238.
126. Acevedo-Torres, K., Berrios, L., Rosario, N., Dufault, V., Skatchkov, S., Eaton, M.
J., Torres-Ramos, C. A. & Ayala-Torres, S. (2009) Mitochondrial DNA damage is
a hallmark of chemically induced and the R6/2 transgenic model of Huntington's
disease. DNA Repair (Amst.) 8: 126-136.
Search Pocayo ::

Custom Search